NIH Aranesp study
Executive Summary
National Cancer Institute study to identify equivalent doses of Aranesp and J&J's Procrit should not be necessary for CMS to revise its reimbursement decision on Amgen's anemia agent, company tells analysts April 22. Amgen, CMS have been involved in "a dense set of discussions...looking at large amounts of clinical data," CEO Kevin Sharer says. "We don't expect...that any trial run by another part of the government will be necessary to come to the right conclusion and...I don't think, at this point...that [CMS sees] that as necessary either," Sharer says. CMS contracted the NCI study when it decided Aranesp should be reimbursed at the same rate as Procrit (1"The Pink Sheet" Nov. 4, 2002, p. 27)...
You may also be interested in...
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.